Exosome-Based Diagnostics and Cell-Free Therapeutics for Traumatic Brain Injury: From Mechanisms to Bedside
Chen M., Gu C., Lai Y., Lin Y., Xu Y., Li X.
Narrative Review, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Nanomedicine (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41869392
- PMCID
- PMC13004130
- DOI
- 10.2147/ijn.s580440
- Citations
- 1
Abstract (original English)
Traumatic brain injury (TBI) is one of the leading neurological disorders worldwide. The complexity of its pathological mechanisms and substantial interindividual variability pose considerable challenges to conventional diagnostic and therapeutic approaches. Exosomes, a subtype of extracellular vesicles, have attracted growing interest due to their excellent biocompatibility and ability to cross the blood-brain barrier, demonstrating considerable potential in TBI diagnosis and treatment. This review focuses on the application of exosomes in the field of TBI, clarifying the pathophysiological mechanisms by which exosomes regulate inflammation, neuronal repair, vascular changes and cognitive function after TBI, and discussing their value as novel biomarkers in the early diagnosis and prognosis assessment of TBI. Subsequently, we summarize the application of exosome tissue engineering in TBI, comb through the preclinical translational basis of exosomes, and analyze the current challenges including standardization of isolation procedures, safety and long-term efficacy. In summary, exosomes provide a novel paradigm for cell-free therapy and precision diagnosis of TBI, and further addressing translational bottlenecks will enable them to exert greater advantages.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.